COVID-19 treatment Archives | Be Korea-savvy
Celltrion’s COVID-19 Candidate Treatment Shows Safety in Clinical Trial

Celltrion’s COVID-19 Candidate Treatment Shows Safety in Clinical Trial

SEOUL, Jan. 3 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its antibody treatment candidate against COVID-19 has shown safety in its clinical trial. Celltrion said it has enrolled 24 healthy volunteers in its global phase one clinical trial and confirmed the safety, tolerability and pharmacokinetics of CT-P63. Separately, Celltrion said [...]

Hyundai Bioscience COVID-19 Treatment Candidate Shows Efficacy with Dexamethasone

Hyundai Bioscience COVID-19 Treatment Candidate Shows Efficacy with Dexamethasone

SEOUL, Dec. 7 (Korea Bizwire) — South Korean biotechnology firm Hyundai Bioscience Co. said Tuesday that the combination of its oral antiviral candidate and dexamethasone showed high efficacy in treating COVID-19 during animal testings. The company is currently re-purposing niclosamide-based CP-COV03 as a potential treatment for the COVID-19 virus. The investigative drug’s indication also includes [...]

Celltrion to Supply COVID-19 Treatment to 9 European Countries

Celltrion to Supply COVID-19 Treatment to 9 European Countries

SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co., an affiliate of South Korean biopharmaceutical giant Celltrion Inc., said Tuesday it has inked a series of deals to supply its COVID-19 antibody treatment to nine European countries. Under the agreement, Celltrion Healthcare — which handles overseas business operations for Celltrion Inc. — will deliver 150,000 [...]

S. Korea OKs Celltrion’s COVID-19 Treatment for Conditional Use

S. Korea OKs Celltrion’s COVID-19 Treatment for Conditional Use

SEOUL, Feb. 5 (Korea Bizwire) — South Korea’s drug safety agency said Friday it has approved pharmaceutical giant Celltrion Inc.’s COVID-19 treatment candidate on several conditions. The conditional marketing authorization of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, marks the country’s first homegrown COVID-19 treatment. The Korean Ministry of Food and Drug Safety said CT-P59 [...]

Relay Medical and Glow LifeTech Report on Successful Phase II Clinical Results for COVID-19 Treatment Candidate Based on Its MyCell Technology™

Relay Medical and Glow LifeTech Report on Successful Phase II Clinical Results for COVID-19 Treatment Candidate Based on Its MyCell Technology™

TORONTO, Jan. 14 (Korea Bizwire) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, and Glow LifeTech Ltd. (“Glow”), a private company in which Relay holds a significant equity interest, are pleased to report on developments related to Glow’s MyCell Technology™ (“MyCell”). Glow LifeTech partner [...]

Celltrion Says its COVID-19 Treatment Cuts Recovery Time, Chance of Severe Cases

Celltrion Says its COVID-19 Treatment Cuts Recovery Time, Chance of Severe Cases

SEOUL, Jan. 13 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its COVID-19 treatment candidate reduces recovery time and the chance of a severe case developing. It was making public clinical data on the second-phase global trial study of the CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. The firm earlier submitted [...]

Celltrion’s COVID-19 Treatment Shows Higher Efficacy than 2 Rivals

Celltrion’s COVID-19 Treatment Shows Higher Efficacy than 2 Rivals

SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Tuesday that its anti-COVID-19 monoclonal antibody treatment has shown higher treatment efficacy compared to its two rival candidates. The Korean Ministry of Food and Drug Safety is currently reviewing conditional approval of Celltrion’s CT-P59, also known as Regdanvimab, a move that could [...]

Daewoong Pharmaceutical Eyes COVID-19 Treatment’s Launch Early Next Year

Daewoong Pharmaceutical Eyes COVID-19 Treatment’s Launch Early Next Year

SEOUL, Dec. 21 (Korea Bizwire) — South Korean drugmaker maker Daewoong Pharmaceutical Co. aims to launch a treatment drug for the novel coronavirus early next year, the company’s chief said Monday. Foistar, an oral protease inhibitor, is currently undergoing phase two clinical trial on COVID-19 patients with mild symptoms. The company aims to release the [...]

Celltrion Eyes Emergency Authorization for COVID-19 Treatment Next Month

Celltrion Eyes Emergency Authorization for COVID-19 Treatment Next Month

SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]